Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
FDA denies Teva Copaxone generic trials petition
ALSUntangled No. 8: Low dose naltrexone for ALS.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Biogen Idec's long-acting beta interferon moves ahead in MS
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Rituximab in paediatric onset multiple sclerosis: a case series.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.

Pages